Notice: This company has been marked as potentially delisted and may not be actively trading. Pluristem Therapeutics (PSTI) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period NBRVF Nabriva Therapeutics plcAugust 18, 2023 | seekingalpha.comPluri CEO Issues Shareholder UpdateJuly 25, 2022 | finance.yahoo.comPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 25, 2022 | benzinga.comPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 25, 2022 | finance.yahoo.comPluristem (PSTI) Phase III Study Misses Goal, Stock DownJuly 14, 2022 | finance.yahoo.comPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture SurgeryJuly 13, 2022 | finance.yahoo.comPluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary GoalJuly 13, 2022 | markets.businessinsider.comPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryJuly 13, 2022 | finance.yahoo.comPluristem: Fiscal Q3 Earnings SnapshotMay 10, 2022 | apnews.comPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New PartnershipMarch 28, 2022 | finance.yahoo.comPluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialMarch 23, 2022 | seekingalpha.comPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood TransfusionsMarch 23, 2022 | finance.yahoo.comPluristem Therapeutics, Inc. Common Stock (PSTI)March 21, 2022 | nasdaq.comPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint VentureMarch 8, 2022 | finance.yahoo.comPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food PlatformFebruary 24, 2022 | finance.yahoo.comThinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?January 12, 2022 | marketwatch.comPluristem Therapeutics (NASDAQ:PSTI) Downgraded to "Hold" at Zacks Investment ResearchZacks Investment Research lowered Pluristem Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday.January 12, 2022 | marketbeat.comIsrael's Tnuva partners with Pluristem to develop cultured cell-based meatJanuary 10, 2022 | msn.comBiotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food PlatformJanuary 10, 2022 | finance.yahoo.comPluristem Climbs On Collaboration With Tnuva Of Israel For Commercialization Of Alternative MeatJanuary 10, 2022 | nasdaq.comPluristem jumps 31% on collaboration with Tnuva to develop cultured cell-based food productsJanuary 10, 2022 | seekingalpha.comBiotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food PlatformJanuary 10, 2022 | finance.yahoo.comPluristem Therapeutics Inc Shares Fall 3.3% Below Previous 52-Week Low - Market MoverDecember 30, 2021 | nasdaq.comPluristem Therapeutics Shares Tumble on Covid-19 Study Failure >PSTIDecember 29, 2021 | marketwatch.comPluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDSDecember 28, 2021 | finance.yahoo.comPluristem: Phase II Studies Of ARDS Associated With COVID-19 Fails To Meet Primary Efficacy EndpointDecember 27, 2021 | nasdaq.comPluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19December 27, 2021 | finance.yahoo.comPluristem Therapeutics (NASDAQ:PSTI) Raised to "Buy" at Zacks Investment ResearchZacks Investment Research upgraded Pluristem Therapeutics from a "hold" rating to a "buy" rating and set a $2.50 target price for the company in a report on Wednesday.December 15, 2021 | marketbeat.comIs Pluristem Therapeutics (NASDAQ:PSTI) Using Too Much Debt?November 1, 2021 | nasdaq.comWill Pluristem Therapeutics (NASDAQ:PSTI) Spend Its Cash Wisely?September 1, 2021 | finance.yahoo.comIceCure Medical Ltd (ICCM.TA)August 9, 2021 | ca.finance.yahoo.comLongeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDSJuly 29, 2021 | markets.businessinsider.com Get Pluristem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW PSTI Media Mentions By Week PSTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTI News Sentiment▼0.000.49▲Average Medical News Sentiment PSTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTI Articles This Week▼00▲PSTI Articles Average Week Get Pluristem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CASI News CRDL News CDTX News CRDF News CHRS News IPHA News PLX News VIGL News OTLK News ADVM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTI) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluristem Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluristem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
